AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9369265 — intervention group
Group type: EXPERIMENTAL
Intervention: SR 49059 (300 mg)
Number of subjects: 12
Study 9369265 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1490537 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention to improve computerized recording of presenting symptoms and problems/diagnoses
Number of subjects: 7983
Study 1490537 — intervention group
Group type: COMPARATOR
Intervention: Control group (manual record)
Number of subjects: 7983
Study 2417834 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (mol. wt 450,000)
Number of subjects: 24
Study 2417834 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran (mol. wt 60,000)
Number of subjects: 24
Study 2417834 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% plasma protein solution
Number of subjects: 24
Study 2417834 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 24
Study 30923187 — intervention group
Group type: EXPERIMENTAL
Intervention: Riociguat
Number of subjects: 0
Study 30923187 — intervention group
Group type: COMPARATOR
Intervention: French non-invasive method
Number of subjects: 0
Study 30923187 — intervention group
Group type: COMPARATOR
Intervention: Swedish/COMPERA methods
Number of subjects: 0
Study 30923187 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk criteria or low-risk stratum at follow-up
Number of subjects: 0
Study 30923187 — intervention group
Group type: EXPERIMENTAL
Intervention: Inoperable or persistent/recurrent CTEPH
Number of subjects: 0
Study 29650348 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious game 'The world of EMPA'
Number of subjects: 224
Study 29650348 — intervention group
Group type: COMPARATOR
Intervention: Digital information package about disabilities
Number of subjects: 224
Study 27178047 — intervention group
Group type: EXPERIMENTAL
Intervention: fasiglifam 25 mg once daily
Number of subjects: 282
Study 27178047 — intervention group
Group type: EXPERIMENTAL
Intervention: fasiglifam 50 mg once daily
Number of subjects: 282
Study 27178047 — intervention group
Group type: EXPERIMENTAL
Intervention: fasiglifam monotherapy
Number of subjects: 282
Study 27178047 — intervention group
Group type: COMPARATOR
Intervention: sulphonylurea combination therapy
Number of subjects: 282
Study 27178047 — intervention group
Group type: EXPERIMENTAL
Intervention: fasiglifam (both doses)
Number of subjects: 282
Study 24731434 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS (high dose left prefrontal repetitive transcranial magnetic stimulation)
Number of subjects: 41
Study 24731434 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 41
Study 24731434 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 41
Study 23005919 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol MDI with valved spacer
Number of subjects: 31
Study 23005919 — intervention group
Group type: COMPARATOR
Intervention: Albuterol MDI with non-valved spacer
Number of subjects: 31
Study 20473771 — intervention group
Group type: EXPERIMENTAL
Intervention: Trigeminal block with 0.8‐mL lidocaine 2%
Number of subjects: 55
Study 20473771 — intervention group
Group type: COMPARATOR
Intervention: Deep sedation and trigeminal injection of 0.8‐mL saline (Control)
Number of subjects: 55
Study 17912933 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspheric IOLs (Acrysof IQ SN6OWF, Tecnis Z9000, Sofport L161AO)
Number of subjects: 250
Study 17912933 — intervention group
Group type: COMPARATOR
Intervention: Spherical IOLs (Acrysof SN6OAT, Sensar AR40e)
Number of subjects: 250
Study 17912933 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspheric IOLs
Number of subjects: 250
Study 16113582 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) and gonadotropin-releasing hormone agonist (GnRHa) treatment
Number of subjects: 38
Study 16113582 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 38
Study 11974545 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary velopharyngoplasty
Number of subjects: 42
Study 10411034 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential BCG and epirubicin (group 1)
Number of subjects: 139
Study 10411034 — intervention group
Group type: COMPARATOR
Intervention: BCG alone (group 2)
Number of subjects: 139
Study 9606452 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (patients whose source pharmacy provided preadmission information)
Number of subjects: 156
Study 9606452 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 156
Study 9606452 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients whose source pharmacy did not provide preadmission information)
Number of subjects: 156
Study 9606452 — intervention group
Group type: COMPARATOR
Intervention: LTC pharmacists
Number of subjects: 156
Study 1883257 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol at higher dosages (mean, 11.6 +/- 4.7 mg/d) for 2 weeks
Number of subjects: 106
Study 1883257 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol at neuroleptic threshold dosages (mean, 3.4 +/- 2.3 mg/d) for 2 weeks
Number of subjects: 106
Study 1883257 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol at higher dosages (mean, 11.6 +/- 4.7 mg/d)
Number of subjects: 106
Study 6870221 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of metronidazole (500 mg over 20 min)
Number of subjects: 27
Study 6870221 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of tinidazole (500 mg over 20 min)
Number of subjects: 27
Study 6870221 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of metronidazole (500 mg)
Number of subjects: 27
Study 6870221 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of tinidazole (500 mg)
Number of subjects: 27
Study 6870221 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal administration of metronidazole (1,000 mg)
Number of subjects: 27
Study 6870221 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal administration of tinidazole (1,000 mg)
Number of subjects: 27
Study 6870221 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal administration of metronidazole (500 mg)
Number of subjects: 27
Study 6870221 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal administration of tinidazole (500 mg)
Number of subjects: 27
Study 6870221 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of either drug
Number of subjects: 27
Study 6870221 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal administration of either drug
Number of subjects: 27
Study 6870221 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal administration of either drug
Number of subjects: 27
Study 6870221 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole
Number of subjects: 27
Study 6870221 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 27
Study 31005915 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based training
Number of subjects: 0
Study 31005915 — intervention group
Group type: COMPARATOR
Intervention: No training (Control)
Number of subjects: 0
Study 29894202 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin intervention during dual clamp in MHD patients
Number of subjects: 33
Study 29894202 — intervention group
Group type: COMPARATOR
Intervention: Insulin intervention during dual clamp in controls
Number of subjects: 33
Study 26781504 — intervention group
Group type: COMPARATOR
Intervention: Advice only
Number of subjects: 9000
Study 26781504 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice with exercise
Number of subjects: 9000
Study 26781504 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice with multifactorial falls prevention (MFFP)
Number of subjects: 9000
Study 24717394 — intervention group
Group type: EXPERIMENTAL
Intervention: CFC training for physicians
Number of subjects: 480
Study 21865014 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Treatment (AT)
Number of subjects: 122
Study 21865014 — intervention group
Group type: COMPARATOR
Intervention: Delayed Treatment Control (DTC)
Number of subjects: 122
Study 20078686 — intervention group
Group type: EXPERIMENTAL
Intervention: C-HAT (currently on heroin-assisted treatment)
Number of subjects: 54
Study 20078686 — intervention group
Group type: EXPERIMENTAL
Intervention: D-HAT (discontinued HAT)
Number of subjects: 54
Study 20078686 — intervention group
Group type: COMPARATOR
Intervention: N-HAT (never received HAT)
Number of subjects: 54
Study 18331607 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin (50 mg bid)
Number of subjects: 14
Study 18331607 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 15845709 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine plus IV morphine via patient‐controlled analgesia (ITM+PCA group)
Number of subjects: 100
Study 15845709 — intervention group
Group type: COMPARATOR
Intervention: IV morphine via patient‐controlled analgesia (PCA‐only group)
Number of subjects: 100
Study 12219854 — intervention group
Group type: EXPERIMENTAL
Intervention: High self-esteem participants
Number of subjects: 0
Study 12219854 — intervention group
Group type: EXPERIMENTAL
Intervention: Low self-esteem participants
Number of subjects: 0
Study 10354965 — intervention group
Group type: EXPERIMENTAL
Intervention: Pleconaril oral capsules (50 to 1000 mg)
Number of subjects: 56
Study 10354965 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 8550116 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50-100 mg per day)
Number of subjects: 65
Study 8550116 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (10-20 mg per day)
Number of subjects: 65
Study 1769321 — intervention group
Group type: EXPERIMENTAL
Intervention: L-sulpiride 25 mg t.i.v./day, p.o. for 30 days
Number of subjects: 30
Study 1769321 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study 6175830 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin 2 mg
Number of subjects: 6
Study 6175830 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimazosin 200 mg
Number of subjects: 6
Study 6175830 — intervention group
Group type: EXPERIMENTAL
Intervention: UK-33,274 4 mg
Number of subjects: 6
Study 6175830 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin and UK-33,274
Number of subjects: 6
Study 6175830 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimazosin
Number of subjects: 6
Study 31091866 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudomonas fluorescens VUPF5 nanocapsules
Number of subjects: 0
Study 31091866 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus subtilis VRU1 nanocapsules
Number of subjects: 0
Study 31091866 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation of metabolites from both bacterial strains
Number of subjects: 0
Study 31091866 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 28043189 — intervention group
Group type: EXPERIMENTAL
Intervention: Andresen Activator (AA)
Number of subjects: 97
Study 28043189 — intervention group
Group type: COMPARATOR
Intervention: Prefabricated Functional Appliance (PFA)
Number of subjects: 97
Study 25234481 — intervention group
Group type: EXPERIMENTAL
Intervention: MEHRIT (social-interaction-based intervention)
Number of subjects: 0
Study 25234481 — intervention group
Group type: COMPARATOR
Intervention: Community treatment group (control)
Number of subjects: 0
Study 23968815 — intervention group
Group type: EXPERIMENTAL
Intervention: METH (30 mg)
Number of subjects: 8
Study 23968815 — intervention group
Group type: COMPARATOR
Intervention: METH (0 mg)
Number of subjects: 8
Study 20223794 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural (CBT) Anger Management group
Number of subjects: 25
Study 20223794 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal Development (PD) Anger Management group
Number of subjects: 25
Study 20223794 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 25
Study 19689661 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg loading dose of clopidogrel followed by 150 mg daily for 1 week prior to angiography
Number of subjects: 120
Study 19689661 — intervention group
Group type: COMPARATOR
Intervention: 300 mg loading dose of clopidogrel
Number of subjects: 120
Study 17804841 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa (40,000 U weekly for a maximum of 3 weeks)
Number of subjects: 1460
Study 17804841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1460
Study 15028824 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy alone (20 Gy over a two-week period plus fluorouracil)
Number of subjects: 289
Study 15028824 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy alone (fluorouracil)
Number of subjects: 289
Study 15028824 — intervention group
Group type: EXPERIMENTAL
Intervention: Both chemoradiotherapy and chemotherapy
Number of subjects: 289
Study 15028824 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 289
Study 11275924 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase (1.5 x 10(6) U over 30‐60 minutes)
Number of subjects: 397
Study 9833860 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine, didanosine, and nevirapine combination therapy
Number of subjects: 0
Study 9833860 — intervention group
Group type: COMPARATOR
Intervention: More sensitive assay with a lower quantification limit of 20 copies/ml
Number of subjects: 0
Study 8008541 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized nursing intervention for 1 year
Number of subjects: 332
Study 8008541 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no specialized nursing intervention)
Number of subjects: 332
Study 2145232 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone 0.5 mg/kg bolus + 2.5 micrograms/kg/minute infusion
Number of subjects: 21
Study 2145232 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone 0.5 mg/kg bolus + 5.0 micrograms/kg/minute infusion
Number of subjects: 21
Study 2145232 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone 0.5 mg/kg bolus + 10.0 micrograms/kg/minute infusion
Number of subjects: 21
Study 2145232 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone 5.0 micrograms/kg/minute infusion without bolus
Number of subjects: 21
Study 2145232 — intervention group
Group type: COMPARATOR
Intervention: Control group (no bolus)
Number of subjects: 21
Study 2145232 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone infusion at rates greater than 5.0 micrograms/kg/minute
Number of subjects: 21
Study 2145232 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone infusion
Number of subjects: 21
Study 6994778 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine (2 to 6 mg daily)
Number of subjects: 16
Study 6994778 — intervention group
Group type: COMPARATOR
Intervention: Clonidine (0.3 to 0.9 mg daily)
Number of subjects: 16
Study 31462582 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive lacosamide
Number of subjects: 343
Study 31462582 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 343
Study 28686778 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% SA topical gel enriched with botanicals
Number of subjects: 25
Study 28686778 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 25
Study 25490610 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day buprenorphine tapering schedule
Number of subjects: 516
Study 25490610 — intervention group
Group type: EXPERIMENTAL
Intervention: 28-day buprenorphine tapering schedule
Number of subjects: 516
Study 23719234 — intervention group
Group type: EXPERIMENTAL
Intervention: Colistin sulphate (50 mg 4×/day) and neomycin sulphate (250 mg 4×/day) for 10 days plus nitrofurantoin (100 mg 3×/day) for 5 days
Number of subjects: 58
Study 23719234 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 23719234 — intervention group
Group type: EXPERIMENTAL
Intervention: Colistin and neomycin treatment
Number of subjects: 58
Study 21035869 — intervention group
Group type: EXPERIMENTAL
Intervention: Alleviated positioning (avoiding supine position for 10 days)
Number of subjects: 69
Study 21035869 — intervention group
Group type: COMPARATOR
Intervention: Facedown positioning (strict facedown for 22 of 24 hours for 10 days)
Number of subjects: 69
Study 21035869 — intervention group
Group type: EXPERIMENTAL
Intervention: Alleviated positioning
Number of subjects: 69
Study 21035869 — intervention group
Group type: COMPARATOR
Intervention: Facedown positioning
Number of subjects: 69
Study 19296969 — intervention group
Group type: EXPERIMENTAL
Intervention: Burch colposuspension
Number of subjects: 0
Study 19296969 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous rectus fascial sling
Number of subjects: 0
Study 19296969 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant surgery
Number of subjects: 0
Study 19296969 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent self‐catheterization
Number of subjects: 0
Study 17719313 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (TMZ) 20 mg, TID for 6 months
Number of subjects: 50
Study 17719313 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual drug therapy) for 6 months
Number of subjects: 50
Study 15586837 — intervention group
Group type: EXPERIMENTAL
Intervention: Organizational intervention to improve guideline implementation
Number of subjects: 5678
Study 15586837 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 5678
Study 11480529 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium
Number of subjects: 39
Study 11480529 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum arabic
Number of subjects: 39
Study 11480529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 9726717 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone (mean daily dose, 640 microg)
Number of subjects: 30
Study 9726717 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol (50 microg)
Number of subjects: 30
Study 8306750 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training for 6 months
Number of subjects: 15
Study 8306750 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 15
Study 2721103 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg of disulfiram daily
Number of subjects: 20
Study 2721103 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg of disulfiram daily
Number of subjects: 20
Study 783029 — intervention group
Group type: EXPERIMENTAL
Intervention: Caved-S
Number of subjects: 45
Study 783029 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacid mixture
Number of subjects: 45
Study 783029 — intervention group
Group type: COMPARATOR
Intervention: Placebo followed by small quantities of antacids
Number of subjects: 45
Study 28471731 — intervention group
Group type: EXPERIMENTAL
Intervention: Ashwagandha root extract (300mg twice daily)
Number of subjects: 50
Study 28471731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 25617166 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Navigator intervention (PNs) providing coaching and assistance for 30 days post-discharge.
Number of subjects: 1510
Study 25617166 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care).
Number of subjects: 1510
Study 23810269 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily physical activity (DPA) assessment using DigiWalker SW-200
Number of subjects: 155
Study 23810269 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional capacity variables (six-minute walking distance, St. George Respiratory Questionnaire activity score)
Number of subjects: 155
Study 23810269 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological variables
Number of subjects: 155
Study 23810269 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower functional status
Number of subjects: 155
Study 23810269 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher functional status
Number of subjects: 155
Study 21314839 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile perfusion using Rotaflow centrifugal pump (60 cycles/min during aortic cross‐clamping)
Number of subjects: 32
Study 21314839 — intervention group
Group type: COMPARATOR
Intervention: Nonpulsatile perfusion using Rotaflow centrifugal pump (nonpulsatile mode during aortic cross‐clamping)
Number of subjects: 32
Study 18823774 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-shot spinal analgesia
Number of subjects: 122
Study 18823774 — intervention group
Group type: COMPARATOR
Intervention: Paracervical block
Number of subjects: 122
Study 16399880 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based standardized communication system (SCS)
Number of subjects: 2022
Study 16399880 — intervention group
Group type: COMPARATOR
Intervention: Control group (1-page copy of emergency department notes by mail)
Number of subjects: 2022
Study 15150821 — intervention group
Group type: EXPERIMENTAL
Intervention: (2)H-octanoic acid saliva test (OST) with 1 MJ meal
Number of subjects: 12
Study 15150821 — intervention group
Group type: EXPERIMENTAL
Intervention: (13)C-octanoic acid breath test (OBT) with 1 MJ meal
Number of subjects: 12
Study 15150821 — intervention group
Group type: COMPARATOR
Intervention: (2)H-octanoic acid saliva test (OST) with 2 MJ meal
Number of subjects: 12
Study 15150821 — intervention group
Group type: COMPARATOR
Intervention: (13)C-octanoic acid breath test (OBT) with 2 MJ meal
Number of subjects: 12
Study 11422002 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole (400 mg on the first day then 200 mg day‐1 for 3 days)
Number of subjects: 14
Study 11422002 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone with itraconazole
Number of subjects: 14
Study 11422002 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone
Number of subjects: 14
Study 9288700 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol valerate/cyproterone acetate (EV/CPA)
Number of subjects: 0
Study 9288700 — intervention group
Group type: COMPARATOR
Intervention: Conjugated estrogens/medroxyprogesterone acetate (CE/MPA)
Number of subjects: 0
Study 9288700 — intervention group
Group type: EXPERIMENTAL
Intervention: Total testosterone and dihydroepiandrosterone sulfate
Number of subjects: 0
Study 9288700 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid stimulating hormone and triiodothyronine
Number of subjects: 0